cyclopentenyl cytosine

inhibits CTP synthetase; used in therapy of colonic neoplasms; structure given in first source; RN given refers to the (1R-(1alpha,4beta,5beta))-isomer

Also Known As:

1-(4-hydroxymethyl-2,3-dihydroxy-4-cyclopenten-1-yl)cytosine; 1-cCyd; 4-amino-1-(4,5-dihydroxy-3-(hydroxymethyl)-2-cyclopenten-1-yl)-2(1H)-pyrimidinone; CPE-c; CPE-cytosine; NSC 375575; NSC-375575; cCyd; cyclopentenyl cytosine, (1R-(1alpha,4beta,5alpha))-isomer; cyclopentenylcytosine

Networked: 42 relevant articles (2 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Bierau, Jörgen: 3 articles (01/2006 - 09/2002)
2.	Caron, Huib N: 3 articles (01/2006 - 09/2002)
3.	Leen, René: 3 articles (01/2006 - 09/2002)
4.	Chen, Shi-You: 2 articles (12/2016 - 10/2013)
5.	Tang, Rui: 2 articles (12/2016 - 10/2013)
6.	Leen, R: 2 articles (04/2008 - 03/2000)
7.	Guchelaar, Henk-Jan: 2 articles (11/2007 - 05/2005)
8.	van Gennip, Albert H: 2 articles (01/2006 - 09/2002)
9.	van Kuilenburg, André B P: 2 articles (01/2006 - 09/2002)
10.	van Gennip, A H: 2 articles (10/2001 - 01/2000)

Related Diseases

1.	Multiple Myeloma 07/03/2014 - "This multicenter, open-label phase 2 trial determined the safety and efficacy of carfilzomib, a novel and irreversible proteasome inhibitor, in combination with cyclophosphamide and dexamethasone (CCyd) in patients with newly diagnosed multiple myeloma (NDMM) ≥65 years of age or who were ineligible for autologous stem cell transplantation. "
2.	Neoplasms (Cancer) 04/25/1997 - "CPE-C has been studied extensively at the preclinical level and has been evaluated in a Phase I clinical trial involving patients with solid tumors. " 01/01/1995 - "We conducted a phase I clinical trial of CPE-C given as a 24-h continuous i.v. infusion every 3 weeks in 26 adults with solid tumors. " 12/01/1993 - "Cyclopentenyl cytosine (CPEC) exhibits oncological activity in murine and human tumor cells and has now entered Phase I clinical trials. " 07/01/1986 - "A subline of L1210 selected for resistance to 1-beta-D-arabinofuranosylcytosine was more sensitive to cyclopentenyl cytosine than the parent tumor line. " 01/01/1997 - "Cyclopentenyl cytosine (CPEC) exerts an antiproliferative effect against a wide variety of human and murine tumor lines, including a panel of human gliosarcoma and astrocytoma lines. "
3.	Carcinoma (Carcinomatosis) 01/01/1999 - "Studies on the antitumor activity and biochemical actions of cyclopentenyl cytosine against human colon carcinoma HT-29 in vitro and in vivo." 05/01/2010 - "In this study, the sensitizing properties of cyclopentenylcytosine (CPEC) on radiation and cisplatin-induced radiosensitization in human squamous lung carcinoma cells were investigated. " 11/24/2000 - "Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo." 07/15/1985 - "The mechanism of action of the cyclopentenyl analogue of cytidine, cCyd, was investigated in human colon carcinoma cell line HT-29. " 11/15/1990 - "We evaluated the interaction of a biochemically active concentration of cyclopentenyl cytosine (CPE-C), an investigational antimetabolite which inhibits CTP synthetase, on the cytotoxicity of arabinosyl-5-azacytosine (Ara-AC) and 1-beta-D-arabinofuranosylcytosine (Ara-C) in HCT 116 colon carcinoma cells. "
4.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2017 - "Here, we synthesized and characterized poly(lactic-co-glycolic-acid) (PLGA) nanoparticles (NPs) modified with the carboxy-terminal-binding domain of CPE (c-CPE-NP) for the delivery of suicide gene therapy to chemotherapy-resistant ovarian cancer cells. " 12/01/2010 - "The aim of this study was to explore the possibility of creating a toxin, C-CPE-ETA', by fusing C-terminal high affinity binding domain of CPE (C-CPE) with a truncated form of Pseudomonas aeruginosa exotoxin A (ETA') and to examine whether C-CPE-ETA' could specifically target CLDN-3, 4 molecule and the targeted toxin was cytotoxic against CLDN-3,4-overexpressing ovarian cancer. "
5.	Vascular Remodeling 10/01/2013 - "Our study uncovered a fundamental difference in CTP biosynthesis between SMCs and ECs during vascular remodeling, which provided a novel strategy by using cyclopentenyl cytosine or other CTPS1 inhibitors to selectively block SMC proliferation without disturbing or even promoting re-endothelialization for effective vascular repair after injury."

Related Drugs and Biologics

1.	Proteasome Inhibitors
2.	Dexamethasone (Maxidex)
3.	Cyclophosphamide (Cytoxan)
4.	carfilzomib
5.	Antibodies
6.	Clostridium enterotoxin
7.	Cytidine Triphosphate (CTP)
8.	Antiviral Agents (Antivirals)
9.	Cisplatin (Platino)
10.	Immunotoxins (Immunotoxin)

Related Therapies and Procedures

1.	Stem Cell Transplantation
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)